// App-Quantinova.ai

: PATIENTS WITH ACUTE CORONARY SYNDROME, ELEVATED ATHEROGENIC LIPOPROTEINS, AND PRIOR CORONARY ARTERY BYPASS GRAFTING DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL

Researchers

Presenter

  • Shaun G. Goodman

Principal Investigators

  • Michael Szarek

  • Vakhtang Chumburidze

  • Deepak L Bhatt

  • Vera Bittner

  • Rafael Alejo Díaz

  • Jay Edelberg

  • Corinne Hanotin

  • Robert A. Harrington

  • Johan Wouter Jukema

  • Sasko Kedev

  • Angele Moryusef

  • Robert Pordy

  • Gabriel Arturo Ramos López

  • Matthew T Roe

  • Margus Viigimaa

  • Harvey D. White

  • Andreas M Zeiher

  • Philippe Gabriel Steg

  • Gregory G. Schwartz

Medical Centers

  • University of Colorado School of Medicine, Denver, TX.

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

  • Genetic Disorder

Disease

  • Acute Coronary Syndromes

  • Coronary Artery Disease

  • Angina

  • Ischemic stroke

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Alirocumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved